Bruce G. Haffty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bruce G. Haffty has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
Darryl Carter
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut
7 shared publicationsLynn D. Wilson
4 shared publications- Atif J. Khan
Memorial Sloan Kettering Cancer Center, New York, NY
3 shared publications Clarence T. Sasaki
3 shared publications- Hwa-Young Son
College of Veterinary Medicine, Chungnam National University, Daejeon 34134, Republic of Korea
3 shared publications Nicole Parisot
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut
3 shared publications
Latest Publications
- 1 April 2013
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 85 (5) , 1168-1171
A Profile of Academic Training Program Directors and Chairs in Radiation Oncology
- 1 April 2013
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 85 (5) , 1168-1171
A Profile of Academic Training Program Directors and Chairs in Radiation Oncology
- 1 July 2012
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 83 (3) , 771-772
National Residency Matching Program (NRMP) Results for Radiation Oncology: 2011 Update
- 1 July 2012
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 83 (3) , 771-772
National Residency Matching Program (NRMP) Results for Radiation Oncology: 2011 Update
- 1 October 2007
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 69 (2) , 326-327
National Residency Matching Program (NRMP) Results for Radiation Oncology: 2007 Update
- 1 October 2007
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 69 (2) , 326-327
National Residency Matching Program (NRMP) Results for Radiation Oncology: 2007 Update
- Open Access
- 24 October 2005
- Published by Springer Nature in Breast Cancer Research
- Vol. 7 (6) , R1017-22
Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer
Introduction: Nipple aspiration is a noninvasive technique for obtaining breast fluids from the duct openings of the nipple for the evaluation of abnormalities associated with breast cancer. Nipple aspirate fluid (NAF) can be elicited from 48 to 94% of healthy women, and its production has been linked to an increased relative risk for breast cancer development. NAF production has been used in studies to guide the selection of ducts for ductal lavage, a procedure in which ducts are cannulated and flushed with saline to collect cells. In a previous multicenter trial to evaluate intraductal approaches in women at high-risk for breast cancer, NAF production was observed in 84% of the subjects. However, we observed a significantly lower proportion of fluid-yielding subjects in a similar series of high-risk women. The purpose of the present study was to identify variables associated with this reduction. Method: Nipple aspiration was performed on 33 high-risk women (defined as having a 5-year Gail model index of more than 1.7, a personal or family history of breast cancer, and/or a BRCA1 or BRCA2 germline mutation) to identify ductal orifices for lavage procedures. Lavage was performed on all fluid-yielding ducts and on nine non-fluid-yielding ducts. Results: Fluid-yielding ducts were identified in 12 of 33 (36%) of the subjects in the present series, compared with 16 of 19 (84%) of the subjects undergoing identical procedures at our facility during a multicenter trial (P = 0.001). Reduced NAF yields were associated with postmenopausal status (P = 0.02), BRCA germline mutations (P = 0.004), and risk reduction therapies, including bilateral salpingo-oophorectomy (BSO) and/or selective estrogen receptor modulators (SERMs; P = 0.009). All nine (100%) of the ductal lavage specimens collected from non-fluidyielding ducts were acellular, in comparison with 3 of 13 specimens from fluid-yielding ducts (P < .001). Conclusion: Analysis of high-risk women in the present series revealed patterns of reduced NAF production and ductal lavage cellularity compared with a previous multicenter trial. The present series included more BRCA-positive women, many of whom had undergone BSO and/or were using SERMs. Our data suggest that endocrine mechanisms associated with these risk-reducing therapies may be related to patterns of diminished breast fluid production.
- 24 October 2005
- Published by Springer Nature in Breast Cancer Research
- Vol. 7 (6) , R1017-22
Open AccessPatterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer
Introduction: Nipple aspiration is a noninvasive technique for obtaining breast fluids from the duct openings of the nipple for the evaluation of abnormalities associated with breast cancer. Nipple aspirate fluid (NAF) can be elicited from 48 to 94% of healthy women, and its production has been linked to an increased relative risk for breast cancer development. NAF production has been used in studies to guide the selection of ducts for ductal lavage, a procedure in which ducts are cannulated and flushed with saline to collect cells. In a previous multicenter trial to evaluate intraductal approaches in women at high-risk for breast cancer, NAF production was observed in 84% of the subjects. However, we observed a significantly lower proportion of fluid-yielding subjects in a similar series of high-risk women. The purpose of the present study was to identify variables associated with this reduction. Method: Nipple aspiration was performed on 33 high-risk women (defined as having a 5-year Gail model index of more than 1.7, a personal or family history of breast cancer, and/or a BRCA1 or BRCA2 germline mutation) to identify ductal orifices for lavage procedures. Lavage was performed on all fluid-yielding ducts and on nine non-fluid-yielding ducts. Results: Fluid-yielding ducts were identified in 12 of 33 (36%) of the subjects in the present series, compared with 16 of 19 (84%) of the subjects undergoing identical procedures at our facility during a multicenter trial (P = 0.001). Reduced NAF yields were associated with postmenopausal status (P = 0.02), BRCA germline mutations (P = 0.004), and risk reduction therapies, including bilateral salpingo-oophorectomy (BSO) and/or selective estrogen receptor modulators (SERMs; P = 0.009). All nine (100%) of the ductal lavage specimens collected from non-fluidyielding ducts were acellular, in comparison with 3 of 13 specimens from fluid-yielding ducts (P < .001). Conclusion: Analysis of high-risk women in the present series revealed patterns of reduced NAF production and ductal lavage cellularity compared with a previous multicenter trial. The present series included more BRCA-positive women, many of whom had undergone BSO and/or were using SERMs. Our data suggest that endocrine mechanisms associated with these risk-reducing therapies may be related to patterns of diminished breast fluid production.
- 1 March 2005
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 2 (3) , 132-133
Can molecular markers predict local, regional and distant metastasis in head and neck cancer?
- 1 March 2005
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 2 (3) , 132-133
Can molecular markers predict local, regional and distant metastasis in head and neck cancer?
- 1 November 2004
- Published by Wiley in The Laryngoscope
- Vol. 114 (11) , 2001-2008
Tissue Microarray Analysis Reveals Prognostic Significance of COX-2 Expression for Local Relapse in T1???2N0 Larynx Cancer Treated with Primary Radiation Therapy
- 1 November 2004
- Published by Wiley in The Laryngoscope
- Vol. 114 (11) , 2001-2008
Tissue Microarray Analysis Reveals Prognostic Significance of COX-2 Expression for Local Relapse in T1???2N0 Larynx Cancer Treated with Primary Radiation Therapy
- 1 March 2004
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (5) , 1678-1684
Prognostic Significance of Cyclooxygenase-2 in Oropharyngeal Squamous Cell Carcinoma
Purpose: To determine the relative prognostic significance of cyclooxygenase (COX)-2 expression in patients with oropharyngeal squamous cell carcinoma (SCC). Experimental Design: This retrospective cohort study included 82 patients with SCC referred to the Department of Therapeutic Radiology at Yale-New Haven Hospital (Connecticut) between 1980 and 1999 who were treated with primary external beam radiotherapy or gross total surgical resection and postoperative radiotherapy. A microarray of archival tumor tissue was constructed and stained with monoclonal antibodies directed against COX-2 and scored for intensity by a pathologist blinded to the clinical outcomes of the patients. COX-2 immunoreactivity and clinicopathological data were analyzed with respect to survival endpoints using bivariate and multivariate techniques. Results: Frequency of COX-2 overexpression was 45%. In multivariate analysis, COX-2 positivity predicted poor 3-year survival (P = 0.02; odds ratio = 0.41; 95% confidence interval, 0.20–0.84). Increasing age was significantly associated with increased 3-year survival (P = 0.03; odds ratio = 1.04; 95% confidence interval, 1.004–1.09). Positive COX-2 status trended toward predicting decreased 3-year disease-free survival. Conclusions: COX-2 was the most important predictor of poor survival in this patient cohort. In patients with oropharyngeal SCC treated with external-beam radiation therapy, overexpression of COX-2 may affect clinical outcome, and COX-2 may therefore prove valuable both as a prognostic factor and as a therapeutic target.
- 1 March 2004
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (5) , 1678-1684
Prognostic Significance of Cyclooxygenase-2 in Oropharyngeal Squamous Cell Carcinoma
Purpose: To determine the relative prognostic significance of cyclooxygenase (COX)-2 expression in patients with oropharyngeal squamous cell carcinoma (SCC). Experimental Design: This retrospective cohort study included 82 patients with SCC referred to the Department of Therapeutic Radiology at Yale-New Haven Hospital (Connecticut) between 1980 and 1999 who were treated with primary external beam radiotherapy or gross total surgical resection and postoperative radiotherapy. A microarray of archival tumor tissue was constructed and stained with monoclonal antibodies directed against COX-2 and scored for intensity by a pathologist blinded to the clinical outcomes of the patients. COX-2 immunoreactivity and clinicopathological data were analyzed with respect to survival endpoints using bivariate and multivariate techniques. Results: Frequency of COX-2 overexpression was 45%. In multivariate analysis, COX-2 positivity predicted poor 3-year survival (P = 0.02; odds ratio = 0.41; 95% confidence interval, 0.20–0.84). Increasing age was significantly associated with increased 3-year survival (P = 0.03; odds ratio = 1.04; 95% confidence interval, 1.004–1.09). Positive COX-2 status trended toward predicting decreased 3-year disease-free survival. Conclusions: COX-2 was the most important predictor of poor survival in this patient cohort. In patients with oropharyngeal SCC treated with external-beam radiation therapy, overexpression of COX-2 may affect clinical outcome, and COX-2 may therefore prove valuable both as a prognostic factor and as a therapeutic target.
Molecular markers for prognosis after isolated postmastectomy chest wall recurrence
BACKGROUND: Local chest wall recurrence after mastectomy occurs in 10–20% of patients with operable breast carcinoma. The objective of the current study was to assess the prognostic value of molecular markers at the time of local recurrence and to compare these markers with clinical variables.METHODS: Between 1975 and 1999, the authors treated 113 patients at their institution for postmastectomy chest wall recurrences with full‐course external beam radiotherapy. Patients who presented primarily with lymph node recurrences or with simultaneous distant metastasis were excluded. Follow‐up from the time of chest wall recurrence was 10.13 years. All clinical and pathologic data from the original diagnosis and from the time of chest wall recurrence were entered into a computerized database. Paraffin‐embedded tumor specimens from the chest wall recurrences were available for 43 patients and were constructed into tissue microarrays for immunohistochemical staining of estrogen receptor, progesterone receptor (PR), p53, HER‐2/neu, and cyclin D.RESULTS: Overall survival after chest wall recurrence for the entire cohort was 46% at 5 years and 28% at 10 years. The distant metastasis–free survival rate was 49% at 5 years and 40% at 10 years. Local‐regional control of disease was achieved in 79% of patients at 10 years. In multivariate analysis, significant factors for distant metastasis after local recurrence were time to recurrence (< 2 years from the original diagnosis to chest wall recurrence) and PR status (distant metastasis–free survival rate: 84% [PR‐positive] vs. 38% [PR‐negative]; P = 0.007). The only significant factor for local‐regional disease progression was HER‐2/neu status. Patients with positive HER‐2/neu status had a local‐regional progression‐free rate of 59%, compared with 92% for patients with negative HER‐2/neu status.CONCLUSIONS: The prognosis for patients after local‐regional recurrence of breast carcinoma is relatively poor. Longer time to local recurrence and positive PR status were associated with favorable distant metastasis–free rates and long‐term survival. Positive HER‐2/neu status was associated with poorer local‐regional control of disease. Implications for systemic therapy and further studies are discussed. Cancer 2004;100:252–63. © 2003 American Cancer Society.
Molecular markers for prognosis after isolated postmastectomy chest wall recurrence
BACKGROUND: Local chest wall recurrence after mastectomy occurs in 10–20% of patients with operable breast carcinoma. The objective of the current study was to assess the prognostic value of molecular markers at the time of local recurrence and to compare these markers with clinical variables.METHODS: Between 1975 and 1999, the authors treated 113 patients at their institution for postmastectomy chest wall recurrences with full‐course external beam radiotherapy. Patients who presented primarily with lymph node recurrences or with simultaneous distant metastasis were excluded. Follow‐up from the time of chest wall recurrence was 10.13 years. All clinical and pathologic data from the original diagnosis and from the time of chest wall recurrence were entered into a computerized database. Paraffin‐embedded tumor specimens from the chest wall recurrences were available for 43 patients and were constructed into tissue microarrays for immunohistochemical staining of estrogen receptor, progesterone receptor (PR), p53, HER‐2/neu, and cyclin D.RESULTS: Overall survival after chest wall recurrence for the entire cohort was 46% at 5 years and 28% at 10 years. The distant metastasis–free survival rate was 49% at 5 years and 40% at 10 years. Local‐regional control of disease was achieved in 79% of patients at 10 years. In multivariate analysis, significant factors for distant metastasis after local recurrence were time to recurrence (< 2 years from the original diagnosis to chest wall recurrence) and PR status (distant metastasis–free survival rate: 84% [PR‐positive] vs. 38% [PR‐negative]; P = 0.007). The only significant factor for local‐regional disease progression was HER‐2/neu status. Patients with positive HER‐2/neu status had a local‐regional progression‐free rate of 59%, compared with 92% for patients with negative HER‐2/neu status.CONCLUSIONS: The prognosis for patients after local‐regional recurrence of breast carcinoma is relatively poor. Longer time to local recurrence and positive PR status were associated with favorable distant metastasis–free rates and long‐term survival. Positive HER‐2/neu status was associated with poorer local‐regional control of disease. Implications for systemic therapy and further studies are discussed. Cancer 2004;100:252–63. © 2003 American Cancer Society.
A comparison of five immunohistochemical biomarkers and HER‐2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early‐onset breast carcinoma
BACKGROUND: The objective of this article was to compare five tumor markers between white women in the U.S. and native Korean women with early‐onset breast carcinoma.METHODS: Sixty Korean women who were diagnosed with breast carcinoma at age 45 years or younger and 60 white women with breast carcinoma who were matched by age were selected for this study. The median age of both groups was 37 years. Paraffin embedded blocks of the primary tumor were processed for immunohistochemical staining of estrogen receptor (ER), progesterone receptor (PR), p53, cyclin D1, and HER‐2/neu.RESULTS: The proportion of tumors that stained positive for ER, PR, p53, and cyclin D1 in the Korean women were 47.5%, 42.4%, 28.8%, and 40.9%, respectively; in the white women, the proportions were 43.9%, 52.6%, 21.1%, and 59.1%, respectively. The differences between the white patients and the Korean patients were not statistically significant with respect to any of those variables. A significant difference was found in the expression of HER‐2/neu. Specifically, positive HER‐2/neu status was observed in 47.5% of Korean women, compared with overexpression in only 15.8% of white women (P < 0.001). Fluorescence in situ hybridization analysis for HER‐2/neu gene amplification on all HER‐2/neu positive samples that scored 2 + and 3 + demonstrated a significant difference (P = 0.007) in gene amplification between the two populations. Differences in HER‐2/neu positivity were observed for the entire cohort as well as among the subsets of patients with negative and positive lymph node status. No association was found between immunoreactivity for the five markers and axillary lymph node metastasis.CONCLUSIONS: The findings of high positivity of HER‐2/neu expression and gene amplification in Korean women with early‐onset breast carcinoma may have potential implications for local and systemic management of breast carcinoma, especially anti‐HER‐2/neu therapy for patients with hormone receptor negativity. Further research will be needed to identify biologic and genetic factors and their effects on the survival between different racial groups. Cancer 2003. © 2003 American Cancer Society.DOI 10.1002/cncr.11703
A comparison of five immunohistochemical biomarkers and HER‐2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early‐onset breast carcinoma
BACKGROUND: The objective of this article was to compare five tumor markers between white women in the U.S. and native Korean women with early‐onset breast carcinoma.METHODS: Sixty Korean women who were diagnosed with breast carcinoma at age 45 years or younger and 60 white women with breast carcinoma who were matched by age were selected for this study. The median age of both groups was 37 years. Paraffin embedded blocks of the primary tumor were processed for immunohistochemical staining of estrogen receptor (ER), progesterone receptor (PR), p53, cyclin D1, and HER‐2/neu.RESULTS: The proportion of tumors that stained positive for ER, PR, p53, and cyclin D1 in the Korean women were 47.5%, 42.4%, 28.8%, and 40.9%, respectively; in the white women, the proportions were 43.9%, 52.6%, 21.1%, and 59.1%, respectively. The differences between the white patients and the Korean patients were not statistically significant with respect to any of those variables. A significant difference was found in the expression of HER‐2/neu. Specifically, positive HER‐2/neu status was observed in 47.5% of Korean women, compared with overexpression in only 15.8% of white women (P < 0.001). Fluorescence in situ hybridization analysis for HER‐2/neu gene amplification on all HER‐2/neu positive samples that scored 2 + and 3 + demonstrated a significant difference (P = 0.007) in gene amplification between the two populations. Differences in HER‐2/neu positivity were observed for the entire cohort as well as among the subsets of patients with negative and positive lymph node status. No association was found between immunoreactivity for the five markers and axillary lymph node metastasis.CONCLUSIONS: The findings of high positivity of HER‐2/neu expression and gene amplification in Korean women with early‐onset breast carcinoma may have potential implications for local and systemic management of breast carcinoma, especially anti‐HER‐2/neu therapy for patients with hormone receptor negativity. Further research will be needed to identify biologic and genetic factors and their effects on the survival between different racial groups. Cancer 2003. © 2003 American Cancer Society.DOI 10.1002/cncr.11703